# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001104659-26-049870
**Filing Date:** 2026-4
**Character Count:** 26903
**Document Hash:** 4e2c1fd4f9246942b8b22a31e31b8a96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-049870.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001104659-26-049870

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**GROUP MEMBERS**: RAVENS SUB, INC.

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcellx, Inc.
- **CENTRAL INDEX KEY:** 0001786205
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472855917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93375
- **FILM NUMBER:** 26903349

**BUSINESS ADDRESS:**
- **STREET 1:** 800 BRIDGE PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 240-327-0603

**MAIL ADDRESS:**
- **STREET 1:** 800 BRIDGE PARKWAY
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**SCHEDULE TO**

**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)<br> OF THE SECURITIES EXCHANGE ACT OF 1934<br> (Amendment No. 3)**

**ARCELLX, INC.**

(Name of Subject Company (Issuer))

**RAVENS SUB, INC.**

a wholly owned subsidiary of

**GILEAD SCIENCES, INC.**

(Names of Filing Persons (Offeror))

**Common Stock, Par Value $0.001 Per Share**

(Title of Class of Securities)

**03940C100**

(Cusip Number of Class of Securities)

**Keeley Cain Wettan<br> Executive Vice President, General Counsel, Legal and Compliance**

**Gilead Sciences, Inc.**

**333 Lakeside Drive**

**Foster City, CA 94404**

**650-574-3000**

(Name, Address and Telephone Number of Person Authorized to<br> Receive Notices and Communications on Behalf of Filing Persons)

**Copy to:**

**Emily Oldshue**

**Nicholas Roper**

**Ropes & Gray LLP**

**800 Boylston Street, Prudential Tower**

**Boston, MA 02199**

◻ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

⌧ third-party tender offer subject
 to Rule 14d-1.

◻ issuer tender offer subject to Rule 13e-4.

◻ going-private transaction subject to Rule 13e-3.

◻ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☒

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

◻ Rule 13e-4(i) (Cross-Border Issuer Tender Offer).

◻ Rule 14d-1(d) (Cross-Border Third Party Tender Offer).

This Amendment No. 3 to the Tender Offer Statement on Schedule TO (this "Amendment No. 3") amends and supplements the Tender Offer Statement on Schedule TO filed by Ravens Sub, Inc., a Delaware corporation ("Purchaser"), and wholly owned subsidiary of Gilead Sciences, Inc., a Delaware corporation ("Parent"), with the U.S. Securities and Exchange Commission (the "SEC") on March 6, 2026 (together with any subsequent amendments and supplements thereto, the "Schedule TO"). The Schedule TO relates to the offer by Purchaser to purchase all outstanding shares of common stock, par value $0.001 per share ("Shares"), of Arcellx, Inc., a Delaware corporation ("Arcellx" or the "Company"), at a price per Share of (i) $115.00 per Share, net to the seller in cash, without interest, subject to any withholding tax, *plus* (ii) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide Sales (as defined in the CVR Agreement (as defined below)) of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029 and the other terms and conditions set forth in a contingent value rights agreement (the "CVR Agreement") to be entered into by and among Parent, Computershare, Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, upon the terms and subject to the conditions described in the Offer to Purchase, dated as of March 6, 2026 (together with any amendments or supplements thereto, the "Offer to Purchase"), and in the related Letter of Transmittal (together with any amendments or supplements thereto and with the Offer to Purchase, the "Offer"), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. This Amendment No. 3 is being filed on behalf of Parent and Purchaser. Unless otherwise indicated, references to sections in the Schedule TO are references to sections of the Offer to Purchase.

Except as otherwise set forth in this Amendment No. 3, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 3. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO.

**Items 1 through 9 and Item 11.**

The information set forth in the Offer to Purchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

"The Offer expired at 5:00 p.m., Eastern Time, on April 27, 2026. The Depositary advised Purchaser that, as of the expiration of the Offer, a total of 38,795,604 Shares were validly tendered and not validly withdrawn, representing, together with shares already owned by Parent, approximately 77.2% of the Shares outstanding as of the expiration of the Offer.

As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Tender Condition, and all other conditions to the Offer were satisfied or waived. Following the expiration of the Offer, Purchaser irrevocably accepted for payment, and will promptly (and in any event within three business days) pay for, all Shares tendered and not validly withdrawn pursuant to the Offer.

Parent and Purchaser expect to complete the acquisition of Arcellx on April 28, 2026 by consummating the Merger pursuant to the Merger Agreement without a vote of the Arcellx stockholders in accordance with Section 251(h) of the DGCL. At the effective time of the Merger, each issued and outstanding Share (other than (i) Shares owned immediately prior to the effective time of the Merger by the Company (including those held in the Company's treasury), (ii) Shares owned both as of the commencement of the Offer and immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or indirect wholly owned subsidiary of Parent, (iii) Shares irrevocably accepted by Purchaser for purchase pursuant to the Offer and (iv) Shares held by stockholders who are entitled to appraisal rights under Section 262 of the DGCL and have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the effective time of the Merger, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL) will be converted into the right to receive, on a per Share basis, (i) $115.00 per Share, net to the seller in cash, without interest, subject to any withholding tax, *plus* (ii) one CVR per Share.

Following the consummation of the Merger, the Shares will be delisted and will cease to trade on the Nasdaq Global Select Market. Parent and Purchaser intend to take steps to cause the termination of the registration of the Shares under the Exchange Act and suspend all of Arcellx's reporting obligations under the Exchange Act as promptly as practicable."

**ITEM 12. EXHIBITS.**

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:

---

| | |
|:---|:---|
| **Index No.** |  |
| [(a)(5)(G)](tm2612748d3_ex99-a5g.htm) | [<u>Press Release issued by Parent, dated April 28, 2026.</u>](tm2612748d3_ex99-a5g.htm) |

---

---

| | |
|:---|:---|
| **Index No.** | |
| [(a)(1)(A)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1a.htm) | [Offer to Purchase, dated as of March 6, 2026.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1a.htm) |
| [(a)(1)(B)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1b.htm) | [Form of Letter of Transmittal.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1b.htm) |
| [(a)(1)(C)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1c.htm) | [Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1c.htm) |
| [(a)(1)(D)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1d.htm) | [Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1d.htm) |
| [(a)(1)(E)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1e.htm) | [Form of Summary Advertisement, published March 6, 2026 in *The New York Times*.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-a1e.htm) |
| [(a)(5)(A)\*](http://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_ex99-1.htm) | [Joint Press Release of Parent and Arcellx, dated February 23, 2026 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Parent with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_ex99-1.htm) |
| [(a)(5)(B)\*](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-1.htm) | [Email message from Parent to Parent investors, dated February 23, 2026 (incorporated by reference to Exhibit 99.1 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-1.htm) |
| [(a)(5)(C)\*](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-2.htm) | [LinkedIn post made by Parent on February 23, 2026 (incorporated by reference to Exhibit 99.2 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-2.htm) |
| [(a)(5)(D)\*](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-3.htm) | [X post made by Parent on February 23, 2026 (incorporated by reference to Exhibit 99.3 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/882095/000110465926018531/tm267075d1_ex99-3.htm) |
| [(a)(5)(E)\*\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926038557/tm2610852d1_ex99-a5e.htm) | [Press Release issued by Parent, dated April 1, 2026.](https://www.sec.gov/Archives/edgar/data/882095/000110465926038557/tm2610852d1_ex99-a5e.htm) |
| [(a)(5)(F)\*\*\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926044653/tm2612074d1_ex99-a5f.htm) | [Press Release issued by Parent, dated April 17, 2026.](https://www.sec.gov/Archives/edgar/data/882095/000110465926044653/tm2612074d1_ex99-a5f.htm) |
| [(a)(5)(G)\*\*\*\*](tm2612748d3_ex99-a5g.htm) | [Press Release issued by Parent, dated April 28, 2026.](tm2612748d3_ex99-a5g.htm) |
| (b) | Not applicable. |
| [(d)(1)\*](http://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_ex2-1.htm) | [Agreement and Plan of Merger, dated as of February 22, 2026, by and among Arcellx, Parent and Purchaser (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Parent with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_ex2-1.htm) |
| [(d)(2)\*](http://www.sec.gov/Archives/edgar/data/1786205/000095017023010610/aclx-ex10_22.htm) | [Collaboration and License Agreement, dated December 8, 2022, by and between Arcellx and Kite Pharma, Inc. (incorporated by reference to Exhibit 10.22 of Arcellx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2023).](http://www.sec.gov/Archives/edgar/data/1786205/000095017023010610/aclx-ex10_22.htm) |
| [(d)(3)\*](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_22.htm) | [Amendment No. 1 to Collaboration and License Agreement, dated November 15, 2023, by and between Arcellx and Kite Pharma, Inc. (incorporated by reference to Exhibit 10.22 of Arcellx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2024).](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_22.htm) |
| [(d)(4)\*](http://www.sec.gov/Archives/edgar/data/1786205/000095017023010610/aclx-ex10_23.htm) | [Common Stock Purchase Agreement, dated December 8, 2022, by and between Arcellx and Parent (incorporated by reference to Exhibit 10.23 of Arcellx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2023).](http://www.sec.gov/Archives/edgar/data/1786205/000095017023010610/aclx-ex10_23.htm) |
| [(d)(5)\*](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_19.htm) | [Common Stock Purchase Agreement, dated November 15, 2023, by and between Arcellx and Parent (incorporated by reference to Exhibit 10.19 of Arcellx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2024).](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_19.htm) |

---

---

| | |
|:---|:---|
| [(d)(6)\*](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_20.htm) | [Amended and Restated Standstill Agreement, dated November 15, 2023, by and between Arcellx and Parent (incorporated by reference to Exhibit 10.20 of Arcellx's Annual Report on Form 10-K filed with the SEC on February 28, 2024).](http://www.sec.gov/Archives/edgar/data/1786205/000095017024022048/aclx-ex10_20.htm) |
| [(d)(7)\*](http://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937dex102.htm) | [Form of Contingent Value Rights Agreement, by and among Parent, Arcellx and the Rights Agent (incorporated by reference to Annex III of Exhibit 10.2 to the Current Report on Form 8-K filed by Parent with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937dex102.htm) |
| [(d)(8)\*](http://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937dex101.htm) | [Form of Tender and Support Agreement, by and among Parent, Purchaser and certain Stockholders of Arcellx (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Parent with the Securities and Exchange Commission on February 23, 2026).](http://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937dex101.htm) |
| [(d)(9)\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-d9.htm) | [Confidentiality Agreement, dated as of February 18, 2026, by and between Parent and Arcellx.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex99-d9.htm) |
| (g) | Not applicable. |
| (h) | Not applicable. |
| [107\*](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex-filingfees.htm) | [Filing Fee Table.](https://www.sec.gov/Archives/edgar/data/882095/000110465926024755/tm267838d1_ex-filingfees.htm) |

---

---

| | |
|:---|:---|
| \* | Previously filed on March 6, 2026 as an exhibit to the Schedule TO. |
| \*\* | Previously filed on April 1, 2026 as an exhibit to the Schedule TO. |
| \*\*\* | Previously filed on April 17, 2026 as an exhibit to the Schedule TO. |
| \*\*\*\* | Filed herewith. |

---

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 28, 2026

---

| | | |
|:---|:---|:---|
| **RAVENS SUB, INC.** | **RAVENS SUB, INC.** | **RAVENS SUB, INC.** |
| By: | /s/ Keeley Cain Wettan | /s/ Keeley Cain Wettan |
|  | Name: | Keeley Cain Wettan |
|  | Title: | Vice President and Secretary |

---

---

| | | |
|:---|:---|:---|
| **GILEAD SCIENCES, INC.** | **GILEAD SCIENCES, INC.** | **GILEAD SCIENCES, INC.** |
| By: | /s/ Andrew D. Dickinson | /s/ Andrew D. Dickinson |
|  | Name: | Andrew D. Dickinson |
|  | Title: | Executive Vice President and Chief Financial Officer |

---

## Ex-99.(A)(5)(G)

**Exhibit 99.(A)(5)(G)**

![](tm2612748d3_ex99-a5gimg001.jpg)

**CONTACTS:**

Ashleigh Koss, Media

Public_affairs@gilead.com

Jacquie Ross, Investors

investor_relations@gilead.com

**GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CEL**

**FOSTER CITY, Calif., April 28, 2026** – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its <u>previously announced</u> acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non-transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing.

The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. By consolidating ownership of anito-cel and eliminating future profit-share, milestone and royalty obligations, Gilead is positioned to accelerate development, streamline decision-making and maximize the long-term potential of the program.

"With the Arcellx acquisition, our focus turns to executing with speed and discipline as we prepare to bring anito-cel to patients," said Cindy Perettie, Executive Vice President and Global Head of Kite. "I want to thank the Arcellx team for their scientific leadership, close collaboration to date and deep expertise they bring as we advance anito-cel. With this acquisition, anito-cel and the differentiated D-Domain BCMA binder will advance within Kite, combining this science with our global manufacturing, regulatory and commercial capabilities to unlock the full value of this potentially transformative therapy for people living with multiple myeloma."

On April 28, 2026, Gilead successfully completed its tender offer for all outstanding shares of common stock of Arcellx and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented, together with shares already owned by Gilead, approximately 77.2% of Arcellx's outstanding shares. Following completion of the offer, Gilead completed the acquisition of Arcellx through a merger of Gilead's wholly owned subsidiary with and into Arcellx, in which shares of Arcellx common stock were cancelled and converted into the right to receive the same $115 per share in cash and one CVR of $5 per share as shares tendered in the offer.

The CVR is payable upon achievement of cumulative global net sales of anito-cel of at least $6.0 billion from launch through the end of 2029.

As a result of the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead and the common stock of Arcellx will be delisted from the Nasdaq Global Select Market.

This transaction is expected to be accounted for as an asset acquisition and reduce Gilead's GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67. Excluding the impact of acquired in-process research and development expenses, Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, and accretive in 2028 and thereafter, subject to FDA approval of anito-cel.

**<u>About Anito-cel</u>**

Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes a novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration.

**<u>About Gilead and Kite Oncology</u>**

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

**<u>About Gilead Sciences</u>**

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

**<u>Forward-Looking Statements</u>**

This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases, forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "seek," "may," "plan," "project," "should," "target," "will," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies' businesses, including Gilead's ability to apply its global manufacturing, regulatory and commercial capabilities and to accelerate the development of anito-cel; regulatory applications; the potential of Arcellx's cell therapy platform; the impact of the transaction on Gilead's diluted EPS; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the risk that the businesses will not be integrated successfully and that other anticipated benefits from the transaction will not be realized; the risk that the milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies' control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Arcellx and the Schedule TO and related tender offer documents filed by Gilead and Ravens Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

*###*

*Gilead, Kite, Arcellx and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.*

*For more information about Gilead, please visit the company's website at <u>www.gilead.com</u>, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).*